SpyGlass Pharma (SGP) Preferred Stock Liabilities (2024 - 2025)
SpyGlass Pharma (SGP) posted quarterly Preferred Stock Liabilities of $204.5 million for Q4 2025, up 181.94% year-over-year from $72.5 million in Q4 2024, and up 181.94% quarter-over-quarter from $72.5 million in Q4 2024.
SpyGlass Pharma (SGP) Preferred Stock Liabilities (2024 - 2025) Analysis & Trends
SpyGlass Pharma (SGP) has reported Preferred Stock Liabilities for 2 consecutive years, with $204.5 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Preferred Stock Liabilities rose 181.94% year-over-year to $204.5 million; the TTM figure through Dec 2025 stood at $204.5 million (up 181.94% YoY), while the FY2025 annual figure was $204.5 million, up 181.94% from the prior year.
- Preferred Stock Liabilities climbed to $204.5 million in Q4 2025 per SGP's latest filing, from $72.5 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $204.5 million in Q4 2025 and bottomed at $72.5 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | SpyGlass Pharma | 876.29 Mn | 876.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 204.54 Mn |
| Dec 31, 2024 | 72.55 Mn |